Most recent update: Tuesday, February 25, 2020 - 11:20

Bariatric News - Cookies & privacy policy

You are here

Liraglutide

Studies demonstrate the effectiveness of post-op liraglutide

Further studies are required to identify clinical predictors that could affect the response to Liraglutide in these patients

Liraglutide can be considered as a safe and effective adjunctive treatment to prevent weight regain after bariatric surgery, according to two studies presented at the UK’s Society for Endocrinology annual conference.

In the first study, ‘Efficacy of liraglutide in weight management post bariatric surgery patients: data from an Emirati cohort’, researchers from Imperial College London Diabetes Centre, Abu Dhabi, UAE, assessed the use of Liraglutide for relapse after bariatric surgery in an Emirati population.

Patients with a previous history of bariatric surgery and a subsequent prescription of Liraglutide 3mg formulation (Saxenda/Victoza), with a minimum follow-up period of 12 weeks were identified from the electronic database. A total of 132 patients (76.5% laparoscopic sleeve gastrectomy, 22% gastric bypass surgery and 1.5% gastric banding) were included in the analysis. At three months follow up, median weight was 90.7kg (81.0–102.2kg), accounting for a weight loss of 3.9% (1.5–6.8%) of the baseline weight. In 44 patients with type 2 diabetes, HbA1c dropped by 0.1% (−0.2 to 0.3%) %.

Seventy-nine patients from the initial cohort had six months follow-up data available and showed a total weight loss of 4.9% (1.1–8.2%) from pre-liraglutide weight. Age, sex and type of bariatric surgery had little or no effect on the weight loss following liraglutide therapy.

The authors concluded that in the Emirati population studied, liraglutide treatment was efficacious as an adjuvant treatment modality for weight loss after bariatric surgery.

In the second study, ‘Outcomes of Liraglutide as treatment for weight regain after bariatric surgery: A 2-year retrospective study’, researchers from Sheikh Khalifa Medical City, Abu Dhabi, UAE, reported the efficacy of Liraglutide as a treatment for weight regain in UAE population who underwent bariatric surgery.

A retrospective analysis was performed on all patients with weight regain after bariatric surgery who received Liraglutide (dose range 0.6 up to 3.0mg/day) while attending bariatric clinic of Sheikh Khalifa Medical City (AD, UAE) over two years (2017-2019).

Fifty-six patients who received Liraglutide for weight regain after bariatric surgery during the study period were identified and 49 patients were included for final analysis as seven patients stopped taking Liraglutide - five due to severe nausea and vomiting and two due to pregnancy. The mean age was 37.9±9.1 years and majority of patients were female (81.6%).

Approximately, 60% had laparoscopic sleeve gastrectomy (n=29), 36.7% had laparoscopic Roux-en-Y gastric bypass (n=18) and 4.1% had Laparoscopic gastric banding (n=2). Mean pre-surgical weight was 123.2±17.8kg and mean BMI was 58.4±10.2. Mean minimal BMI after surgical intervention was 33.5±5.1 and mean weight was 85.7±12.9kg. Mean weight at Liraglutide initiation was 95.1±13.3kg and mean BMI of 36.9±4.4. After three months, mean weight and BMI reduction were 5.4±9.8kg and 1.3±1.1, respectively (p<0.01).

Liraglutide can be considered as a safe and effective adjunctive treatment for weight regain after bariatric surgery, the researchers concluded however, further studies are required to identify clinical predictors that could affect the response to Liraglutide in these patients.

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.